Grouped-level disorder | Count | Overall prevalence % | 95% CIa | Female prevalence % | Male prevalence % | P-Valueb | Median age (years) |
---|---|---|---|---|---|---|---|
Cutaneous | 468 | 22.7 | 20.9–24.6 | 19.9 | 25.2 | 0.004 | 8.3 |
Dental | 367 | 17.8 | 16.2–19.6 | 19.4 | 16.6 | 0.096 | 8.9 |
Aural | 254 | 12.3 | 11.0–13.8 | 10.5 | 13.9 | 0.020 | 8.9 |
Claw/nail | 179 | 8.7 | 7.5–10.0 | 9.3 | 8.2 | 0.365 | 8.4 |
Musculoskeletal | 162 | 7.9 | 6.7–9.1 | 8.9 | 7.0 | 0.115 | 9.3 |
Enteropathic | 146 | 7.1 | 6.0–8.3 | 8.2 | 6.2 | 0.087 | 8.0 |
Ophthalmological | 143 | 6.9 | 5.9–8.1 | 7.5 | 6.5 | 0.356 | 10.8 |
Anal sac | 127 | 6.2 | 5.2–7.3 | 6.9 | 5.6 | 0.221 | 7.3 |
Obesity | 126 | 6.1 | 5.1–7.2 | 7.1 | 5.3 | 0.092 | 7.2 |
Mass-associated | 109 | 5.3 | 4.4–6.4 | 5.9 | 4.7 | 0.205 | 11.7 |
Neoplastic | 101 | 4.9 | 4.0–5.9 | 4.5 | 5.2 | 0.418 | 11.3 |
Parasite infestation | 96 | 4.7 | 3.8–5.7 | 5.0 | 4.4 | 0.543 | 7.3 |
Behavioural | 77 | 3.7 | 3.0–4.7 | 2.9 | 4.5 | 0.051 | 7.6 |
Lower respiratory tract | 45 | 2.2 | 1.6–2.9 | 3.2 | 1.4 | 0.005 | 11.8 |
Cardiac | 40 | 1.9 | 1.4–2.6 | 1.9 | 2.0 | 0.904 | 12.5 |
Upper respiratory tract | 39 | 1.9 | 1.4–2.6 | 1.4 | 2.3 | 0.111 | 8.9 |
Endocrine | 38 | 1.8 | 1.3–2.5 | 2.1 | 1.6 | 0.403 | 11.1 |
Urinary | 38 | 1.8 | 1.3–2.5 | 2.9 | 1.0 | 0.002 | 12.7 |
Traumatic | 33 | 1.6 | 1.1–2.2 | 1.2 | 2.0 | 0.143 | 5.3 |